Toronto-based Blair Health announced Monday it has closed CAD $4.24 million in pre-seed funding, bringing its total raise to CAD $4.5 million as it looks to expand a platform that aims to make specialist care more accessible through nurse practitioners and family physicians.
BDC Capital's Thrive Venture Fund, Accelia Capital and Ogaei co-led the round, with participation from the Ontario Centre of Innovation. The funding, which closed in July and was announced in September, came through a combination of SAFE and convertible notes and will support engineering hires, U.S. expansion, clinical operations and growth of the company's provider network.
The startup's premise is straightforward but ambitious: encode specialist medical protocols into software that generalist clinicians can use to deliver care in areas like menopause, urology, pelvic health and clinical nutrition. Subspecialists oversee complex cases, but the day-to-day work happens with providers who might not otherwise feel equipped to handle these conditions at a specialist level.
Blair Health went live with direct-to-consumer subscriptions in May and now operates across all Canadian provinces and six U.S. states, according to the company. Since launch, it has served more than 2,300 users, with follow-up visits accounting for 55 to 65 percent of steady-state appointments. Employer contracts, which were nearly nonexistent in 2025, made up roughly half of revenue in the first half of this year, according to the company.
That employer traction includes a paid pilot with Fairmont Royal York that converted into a recurring contract. Ian McLaren, the hotel's health and wellness manager, noted that even companies with robust wellness programs often have gaps in coverage. The company has assembled an advisory board that includes Kelly Davis, chief people officer at 123Dentist; Michael Ventrone, formerly vice president of global benefits at Honeywell; and Robin Rees, previously senior vice president of HR business partner at Donnelley Financial Solutions.
Co-founder and CEO Madge Rumman comes from product leadership roles at PayBright, which Affirm acquired, and at Cadre, later bought by Yieldstreet. Her co-founder, Dr. Lindsay Shirreff, is an OB/GYN at Mount Sinai Hospital and assistant professor at the University of Toronto, where she completed fellowships in minimally invasive gynecologic surgery and mature women's health. Dr. Sarah Peltz at Mackenzie Health oversees the urology vertical, while Dr. Pooja Singhal, a gastroenterologist and obesity medicine specialist, leads nutrition and weight management.
The business model offers three tiers. A 12-month plan runs CAD $49.99 monthly and includes four provider appointments annually. A six-month option costs CAD $69.99 per month with two appointments. Pay-as-you-go users pay CAD $25 monthly for platform access, CAD $200 for an initial appointment and CAD $100 for follow-ups. All plans qualify for HSA reimbursement.
Wait times help explain the appeal. A GreenShield survey published in March found one in three Canadian women wait at least two years for effective menopause support. The Menopause Foundation of Canada notes specialist wait times frequently stretch 12 to 18 months or longer.
The market has drawn substantial attention south of the border. Midi Health, a U.S. competitor, raised $100 million in a Series D in February at a valuation north of $1 billion. Evernow pulled in $28.5 million in a 2022 Series A and has since partnered with Clearblue and Oura. Alloy Women's Health secured $16 million in a Series A last November.
"The fundamental problem in healthcare today is that the traditional model for delivering specialist care doesn't scale," Rumman said in a statement. She later told Fierce Healthcare that clinicians retain final decision-making authority, but Blair provides "specialist-level structure to do it."
Dr. Shirreff said the company's menopause pathway "performs at 98.7% clinical accuracy," a company-reported metric that has not been independently verified.
Investors framed the opportunity in familiar terms. Roxanne Turcotte, senior vice president of inclusive and government funds at BDC, called expanding access to specialized care "a significant opportunity to improve outcomes for women." Catherine Poulin-Filion, partner at Accelia Capital, described women's health as "one of the largest underserved opportunities in healthcare."
Blair Health plans to deploy the fresh capital toward deepening its U.S. presence and adding clinical capacity in Canada, where demand has perhaps outpaced what the founders initially expected.
